HISTORY
- 2024
-
- 01
- MST-MPA126’s Patent Granted (mRNA mass production)
- 2023
-
- 11
- Launch of ProMEPS™ (MEPS-AMS, a fully automated robotic system for MPS modeling)
- 11
- Award from the Minister of Trade, Industry, and Energy (MOTIE), ‘Innovative and Fast-Growing Bio Company'
- 11
- Confirmed non-clinical efficacy of MG-GHC24 (Nanomedicine for Glioblastoma) in patient tissues
- 07
- Signing of a Joint Research Agreement about brain tumors (GBM) with ChaBio Hospital
- 07
- Signing of a Cooperative Agreement about evaluation and validation of the Microphysiological System with K-BIO Health
- 06
- MEPS-TBC WL, MEPS-AMS, MG-PLP’s Patent Applications
- 05
- Signing of Research Service Contract using MEPSGEN Microphysiological System
- 05
- Signing of an Agreement to develop extracellular matrix biomaterials with Cellartgen
- 05
- Signing of MOU for Research Services with CRO companies; Corestem Chemon and Woojung Bio
- 05
- MG-PE3’s Patent Registration(Korea)
- 04
- MG-PP3 and MG-GTX13’s Patent Applications
- 03
- MST-SC01(LNP Mass Production Chip)’s Patent Application
- 01
- MEPS-TBC WL, CH, HT’s Design Applications
- 01
- Signing of a Collaborative Research Agreement with Georgia Tech, USA
- 2022
-
- 12
- Initiating nanoparticle manufacturing and mass production business
- 07
- Series B - KDB Bank / DONG-A SOCIO HOLDINGS / KOLON Investment / KIWOOM Securities Co., Ltd. / CEO of the DB, Nam Ho Kim
- 06
- LNP mass production technology patent application (Microfluidic technology)
- 06
- MG-G101 patent application
- 03
- MEPS-TBC cryopreservation patent grant
- 2021
-
- 11
- MG-PE3 PCT application
- 09
- MEPS-TBC, Manufactured & Released
- 08
- Series A (Bridge) – Korea Investment Partners Co., Ltd / SBI Investment Korea Co., Ltd. / KNOTUS Co., Ltd. / Tiumbio Co., Ltd
- 04
- MG-PE3 patent granted in Republic of Korea
- 03
- Started CRO evaluation of MG-PE3, new drug candidate for Alzheimer's disease - 1st Drug efficacy
- 02
- Kicked off MEPS-BBB research service using new drug candidates with pharmaceutical companies
- 01
- Expansion & relocation of the office, R&D center, and production facility (Hanyang Tower, 12, Beobwon-ro-11-gil, Songpa-gu, Seoul, Rep. of Korea)
- 2020
-
- 12
- Finished PK/PD CRO evaluation of MG-PE3, new drug candidate for Alzheimer's disease
- 10
- Venture Business Certification
- 08
- MEPS-TBC patent application (KR/US/PCT) & design application (KR/US/EU) MG-PE3 patent application (KR)
- 08
- Series A – Korea Investment Partners Co., Ltd / Tiumbio Co., Ltd
- 05
- Finalized technology transfer agreement with Georgia Tech. Registered Mepsgenlab as a subsidiary of Mepsgen
- 2019
-
- 09
- Founded Mepsgenlab Inc. (USA)
- 08
- Founded Mepsgen Co., Ltd. (Rep. of Korea)
Sitemap
